IP Library Granted Patent US 12,171,877
Granted Patent B2
US 12,171,877 · App. 16/270,259 · Granted Dec 24, 2024

Materials and methods for delivering compositions to selected tissues

Inventors: William R. Freeman (Del Mar, CA); Michael J. Sailor (La Jolla, CA); Lingyun Cheng (San Diego, CA)
Assignee: The Regents of the University of California
A61K9/143A61K9/0019A61K9/0051A61K9/14A61K9/5115A61K9/7007A61K31/573A61K31/7088A61K38/482A61K39/395A61K39/44C25F3/12A61K2039/505A61K2039/54C12Y304/21073
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,171,877
App. No.
16/270,259
Granted
Dec 24, 2024
Kind
B2
Abstract

This invention relates to devices, systems and methods for delivering preprogrammed quantities of an active ingredient to a biological system over time without the need for external power or electronics.

Claims (13)

1. A composition comprising:

a porous particulate material comprising silicon dioxide, the porous particulate material having been heated in an oxidizing environment at a temperature at or above 800° C.; and

a drug or biologically active material within the porous particulate material.

2. The composition of claim 1 , wherein the porous particulate material is a microscopic porous particulate material.

3. The composition of claim 1 , wherein the porous particulate material displays a particle size of between about 0.1 μm and 100 μm.

4. The composition of claim 1 , wherein the porous particulate material displays a particle size of between about 1 μm and 100 μm.

5. The composition of claim 1 , wherein the porous particulate material displays a porosity of between about 40% and 80%.

6. The composition of claim 1 , wherein the porous particulate material displays a layered nanostructure.

7. The composition of claim 1 , wherein the porous particulate material further comprises a polymeric material.

8. The composition of claim 1 , wherein the drug or biologically active material is selected from the group consisting of: an angiostatic steroid, a metalloproteinase inhibitor, a VEGF binding drug, a pigment epithelium derived factor, an 8-mer peptide fragment of urokinase, a modified RNA, a modified DNA, a fragment derived from an immunoglobulin, and dexamethasone.

9. The composition of claim 1 , wherein the drug or biologically active material is bevacizumab, ranibizumab, or pegaptanib.

10. The composition of claim 1 , wherein the pores are selectively dimensioned to obtain a desired reflective wavelength.

11. A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2024
From: FREEMAN, WILLIAM R.; SAILOR, MICHAEL J.; CHENG, LINGYUN
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 069188/0461 →
CONFIRMATORY LICENSE Recorded Aug 2, 2022
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 061047/0172 →
Continuity (3)
Continuation 12668349
Provisional Application 60948816 · Jul 10, 2007
Related Publication 20200009053A1 · Jan 9, 2020